TPG’s Par Pharmaceutical has agreed to acquire JHP Pharmaceuticals for US$490 M in cash in order to add branded and generic sterile injectables to its product offering. The deal comes only a year after Warburg Pincus acquired the company for US$195 M. With the acquisition, Par will gain access to JHP’s portfolio of 14 marketed speciality injectables and 34 generic pipeline candidates, 17 of which have been filed for US FDA approval. Sterile injectables comprise high-barrier-to-entry products that are difficult to manufacture and which have been the subject of numerous drug recalls and shortages in recent years.